NEW
YORK, May 16, 2024 /PRNewswire/ -- Lindus
Health, the "anti-CRO" running radically faster, more reliable
clinical trials for life science pioneers, has announced its
collaboration with Acinonyx Bio, a biotechnology company that uses
a unique mix of ingredients made from predominantly plants to kill
different types of bacteria, fungi, and viruses effectively, in a
cosmetics clinical trial to investigate their topical cream's
ability to treat inflammatory acne.
Inflammatory acne is characterized by red, swollen, and sore
blemishes, providing physical discomfort and psychological stress
due to its persistent nature and potential to leave permanent
scarring. Acne is the most common skin condition in the US,
affecting approximately 50 million people.
This study aims to target Propionibacterium acnes (P.
acnes), a bacterium that plays a significant role in the
development of inflammatory acne. In in vitro studies, it was
revealed Acinonyx Bio's topical cream, ACX, killed P. acnes as
rapidly as does benzoyl peroxide, a widely used acne treatment.
Benzoyl peroxide products, however, have recently garnered
attention for containing a carcinogen, prompting some consumers to
seek alternative therapies to manage their acne. ACX does not
contain this associated carcinogen in its formulation, and it
reduces sebum production, unclogs pores, and absorbs rapidly into
the skin to lead to a more rapid clinical effect.
The clinical trial will recruit patients with moderate to severe
inflammatory acne and will be carried out under a
decentralized clinical trial (DCT) model, providing
patients with the flexibility to participate in this essential
research within the comfort of their real-world environments.
Participants will use the investigational product for a period of
six weeks and provide photos for medical assessment as well as
feedback on the effectiveness of the topical cream and their
satisfaction with the product.
Lindus Health, responsible for providing end-to-end study
management, including protocol development, regulatory submissions,
recruitment, monitoring, data management and more, will leverage
their in-house virtual site and digital marketing capabilities to
carry out patient recruitment via digital advertising. They will
also design a dedicated study website with pertinent trial
information including leveraging their proprietary eClinical
platform, CitrusTM, for patients to easily complete
pre-screening and eConsent.
"Lindus Health's involvement in this study underpins our
commitment to helping our partners bring safe and effective
dermatological therapies to market. Inflammatory acne can
significantly diminish quality of life," states Michael Young, co-founder of Lindus Health. "We
are enthusiastic about the opportunity to leverage our unique
technical and service-based capabilities in another dermatology
study, building on our vast experience in this space."
"We are optimistic about the development of our topical cream
and the effect it will have on patients," says Alex Michalow, CEO at Acinonyx Bio. "We are
incredibly excited to be working with Lindus Health to bring our
study to life and aid in the overall journey of potentially
bringing a safer alternative to the hands of individuals suffering
from inflammatory acne."
Positive results from this trial would further emphasize the
potential of this novel topical cream in the utility of improving
appearance in those who experience inflammatory acne.
For more information, please visit www.lindushealth.com
About Lindus Health
Lindus Health is an anti-CRO
running radically faster and more reliable trials for life science
pioneers – bringing ground-breaking treatments to patients more
quickly. Lindus Health does this thanks to a commercial model
that aligns incentives (fixed-priced quotes per study, with
milestone-based payments), marrying a world-class clinical
operations team with its unique software platform, and access to 30
million Electronic Health Records. Clinical trials are the biggest
bottleneck to advances in healthcare and by removing this
constraint they aim to improve health for everyone. They handle the
end-to-end execution of clinical studies, including design, patient
recruitment, clinical data capture, monitoring and project
management.
To date, Lindus Health has delivered more than 90 trials across
the US, UK and Europe to tackle a
range of conditions including diabetes, asthma, acne, social
anxiety, major depressive disorder, hypertension, chronic fatigue
syndrome and insomnia.
The company was named after James
Lind, who pioneered the first clinical trial and treatment
for scurvy, and co-founded by Michael
Young, a former Special Adviser to the UK Prime Minister on
Life Sciences, and Meri Beckwith, a
former life sciences investor.
Lindus Health has raised over $24M
from investors including Peter
Thiel, CREANDUM, Firstminute Capital, Presight Capital,
Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.
About Acinonyx Bio
Acinonyx Bio was founded by a
practicing doctor who developed an antimicrobial technology that
uses primarily food grade, mostly plant oil based, ingredients. The
unique combination of ingredients shows high kill rates vs.
numerous bacteria, fungi, and viruses.
Media Contact:
Jodi
Perkins
Amendola for Lindus Health
jperkins@acmarketingpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lindus-health-announces-cosmetics-clinical-trial-with-acinonyx-bio-to-evaluate-an-alternative-to-benzoyl-peroxide-for-inflammatory-acne-302146936.html
SOURCE Lindus Health